Apolipoprotein B (ApoB)
ApoB is the main structural protein on LDL, VLDL, IDL, and Lp(a) particles, with one ApoB molecule per atherogenic particle. It therefore counts the total number of plaque-forming lipoproteins and is considered a more accurate cardiovascular risk marker than LDL cholesterol, especially in people with insulin resistance, high triglycerides, or discordant LDL values.
Units: mg/dL; some labs report g/L (g/L = mg/dL ÷ 100, so 100 mg/dL = 1.0 g/L). Check the units on your report before comparing to any range here.
Optimal range: who says what
Institutions, researchers and practitioners draw the line in different places. Each position is listed with who holds it and, where a document states it, a link. How we verify ranges.
- Institution or study<100 mg/dL moderate risk; <80 high risk; <65 very high risk2019 ESC/EAS dyslipidaemia guidelinesPreventive-cardiology practitioners commonly target lower still
- Institution or study≥130 mg/dL is a risk-enhancing factor2018 AHA/ACC cholesterol guidelineCorresponds to an LDL-C of 160 mg/dL or more; the guideline suggests measuring ApoB when triglycerides are 200 mg/dL or higher
- Named practitioner<90 mg/dL (<60 for those with high risk of arterial occlusion)Life Extension · Lab Testing Protocol (Suggested Optimal Ranges)Disclosure: Life Extension sells lab panels that appear in our blood-test comparisons.
- Named practitioner<70 mg/dLTracey O'Shea (Kresser Institute) · The Lipid Panel Was Fine. The Patient Was Not: A Case in Advanced Cardiovascular Risk Assessment
- Lab reference intervalAbout 50-150 mg/dL (MedlinePlus); labs varyWhat a lab report flags against. A lab interval is not an optimal target.
Practitioner targets are individual positions, often tighter than guideline ranges. Each was checked against its article before publishing.
19 of 21 itemized panels
Lipid Panel / Cardiovascular Health
What is Apolipoprotein B (ApoB)?
Apolipoprotein B (ApoB) is the primary structural protein of atherogenic (artery-clogging) lipoprotein particles, including LDL, VLDL, and Lp(a). Each atherogenic particle contains exactly one ApoB molecule, making ApoB a direct count of the total number of potentially harmful cholesterol particles circulating in your blood. This makes ApoB a more accurate predictor of cardiovascular risk than LDL cholesterol alone.
Unlike LDL cholesterol, which measures the amount of cholesterol within LDL particles, ApoB counts the actual number of particles. This distinction is crucial because particle number is a stronger predictor of atherosclerosis than cholesterol content. Two people with identical LDL cholesterol levels can have very different ApoB levels—one might have many small cholesterol-poor particles (high ApoB, higher risk), while the other has fewer large cholesterol-rich particles (lower ApoB, lower risk).
ApoB testing has emerged as a superior biomarker for cardiovascular risk assessment, particularly useful in cases of metabolic syndrome, diabetes, and high triglycerides where traditional LDL cholesterol measurements can be misleading. Many cardiologists and longevity medicine practitioners now consider ApoB the single best lipid marker for predicting heart disease risk. It captures all atherogenic particles in a single measurement, providing a more comprehensive cardiovascular risk assessment than standard lipid panels.
Why Apolipoprotein B Is Essential
- Most accurate single predictor of cardiovascular disease risk
Interpretation bands (curated, PMID-backed)
Holder: OptimizeBiomarkers editorial synthesis of: Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association (Soffer et al., 2024); Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis (Boekholdt et al., 2012); Association of apolipoprotein B with all-cause and cardiovascular mortality among adults: Results from the National Health and Nutrition Examination Surveys (Yan et al., 2023). No single paper sets these cutoffs; for attributed targets see who says what.
Low40-59 mg/dL▼
- Low atherogenic particle burden
- Below the 2019 ESC/EAS target for very high-risk patients (<65 mg/dL)
Intermediate60-89 mg/dL▼
- Within the ESC/EAS target for moderate risk (<100 mg/dL)
- The ESC/EAS target for high risk is <80 mg/dL, so the top of this band is above it
Very Low<40 mg/dL▼
Rarely problematic; may occur with certain genetic conditions or medications.
Higher≥90 mg/dL▼
- More atherogenic particles
- At or above Life Extension's <90 mg/dL target; the 2018 AHA/ACC guideline counts 130 mg/dL or more as a risk-enhancing factor
- Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association.
- Association of LDL cholesterol, non-HDL cholesterol, and apolipoprotein B levels with risk of cardiovascular events among patients treated with statins: a meta-analysis.
- Association of apolipoprotein B with all-cause and cardiovascular mortality among adults: Results from the National Health and Nutrition Examination Surveys.
What raises or lowers Apolipoprotein B
Causes of high Apolipoprotein B
- Genetic factors (familial hypercholesterolemia, familial combined hyperlipidemia)
- Diet high in saturated fat and trans fat
- Obesity
- Metabolic syndrome
- Insulin resistance
- Hypothyroidism
- Chronic kidney disease
- Nephrotic syndrome
- Sedentary lifestyle
- Smoking
Causes of low Apolipoprotein B
- Genetic abetalipoproteinemia (extremely rare)
- Severe malnutrition
- Hyperthyroidism
- Chronic liver disease
- Aggressive lipid-lowering therapy (desired in cardiovascular prevention)
Symptoms when Apolipoprotein B is high or low
When high
No direct symptoms; elevated ApoB silently accelerates atherosclerosis over years/decades, eventually manifesting as coronary artery disease, stroke, or peripheral arterial disease. May be associated with xanthomas (fatty deposits) in genetic dyslipidemia.
When low
Low ApoB causes no symptoms. Very low levels occur with rare inherited conditions (abetalipoproteinemia, hypobetalipoproteinemia), severe malnutrition or liver disease, and with intensive lipid-lowering therapy.
How to move Apolipoprotein B
Effect sizes (how much something moves the marker) appear only where the paper cited under the item states them. Talk to your clinician before starting or changing any medication or supplement.
Plant Sterols and Fiber
Consume 2-3g daily of plant sterols/stanols from fortified foods or supplements. Increase soluble fiber intake to 10-25g daily through oats, legumes, vegetables, and psyllium. Both lower LDL by reducing cholesterol absorption. In a meta-analysis of randomised trials, plant sterols and stanols at 0.6-3.3 g daily lowered LDL cholesterol by 6-12% on average (Ras 2014).
Dietary Pattern Modification
Adopt a Mediterranean, whole-food plant-based, or Portfolio diet pattern emphasizing unsaturated fats, minimizing saturated fat (<7% of calories), and eliminating trans fats. Replace refined carbohydrates with whole grains. These patterns reduce ApoB through multiple mechanisms.
Weight Loss and Exercise
Achieve healthy body weight and exercise regularly (150+ minutes weekly of moderate-vigorous activity). Losing excess weight lowers ApoB. Exercise improves particle clearance and reduces hepatic VLDL production. Combination provides additive benefits.
Lipid-Lowering Medication
Statins are first-line when lifestyle is not enough. The 2018 AHA/ACC cholesterol guideline lists ApoB of 130 mg/dL or higher as a risk-enhancing factor that favors starting a statin. In very high-risk patients whose LDL cholesterol stays at 70 mg/dL or above on a maximally tolerated statin, it is reasonable to add ezetimibe, then a PCSK9 inhibitor (evolocumab, alirocumab) (Grundy 2018). Drug choice and targets are for you and your prescriber.
When to retest
- Fasting is not required: ApoB is not affected by fasting or non-fasting status (Nordestgaard 2016, EAS/EFLM consensus).
- After starting or changing a statin or other lipid-lowering drug: the 2018 AHA/ACC guideline repeats lipid measurement 4 to 12 weeks later, then every 3 to 12 months as needed (Grundy 2018).
- Once stable and at goal: Every 6-12 months is common practice.
- After diet or weight changes alone: Retest after about 3 months.
Scientific Evidence
ApoB Particle Number and Atherosclerosis
Every VLDL, LDL, and Lp(a) particle carries one ApoB molecule, and cholesterol enters the artery wall only inside ApoB particles. Sniderman and colleagues review evidence that ApoB measures atherogenic risk more accurately than LDL cholesterol or non-HDL cholesterol, because the number of particles trapped in the artery wall drives plaque formation.
Source: Apolipoprotein B Particles and Cardiovascular Disease: A Narrative Review.
LDL-C, Non-HDL-C, and ApoB on Statins
An individual-patient meta-analysis of 8 statin trials (62,154 patients) found on-treatment LDL-C, non-HDL-C, and ApoB each predicted major cardiovascular events (hazard ratios per SD 1.13, 1.16, and 1.14). Non-HDL-C was the strongest; ApoB did not differ significantly from LDL-C.
AACC Position on ApoB
A position statement from the AACC Lipoproteins and Vascular Diseases Division concluded that ApoB measures LDL particle concentration better than LDL-C and is a more reliable indicator of risk, and proposed adding ApoB to the routine lipid panel alongside LDL-C.
Very Low LDL on a PCSK9 Inhibitor
In FOURIER, 27,564 statin-treated patients with atherosclerotic disease received evolocumab or placebo. LDL cholesterol fell from a median 92 to 30 mg/dL, and the primary cardiovascular endpoint fell 15% (hazard ratio 0.85) over 2.2 years, with no excess of adverse events other than injection-site reactions.
Source: Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
Measuring Atherogenic Lipoproteins
A European Atherosclerosis Society and EFLM consensus panel found LDL-C, non-HDL-C, and ApoB comparable as predictors of cardiovascular events, and no consistent evidence yet that ApoB-targeted treatment prevents more events than LDL-targeted treatment. It recommends non-HDL-C or ApoB as a secondary target in mild to moderate hypertriglyceridemia, where LDL-C is less accurate.
Which Providers Test Apolipoprotein B (ApoB)?
Cheapest: Oura Health Panels at $99/year. Most comprehensive: Function Health, 160+ biomarkers for $365/year.
19 panels that include it, cheapest first
| Provider | Annual Cost | Total Biomarkers | $/Biomarker |
|---|---|---|---|
| $99 | 50 | $1.98 | |
| $190 | 100+ | $1.90 | |
| $250 | 65 | $3.85 | |
| $297 | 100+ | $2.97 | |
 Labcorp OnDemand | $338 | 50+ | $6.76 |
 Superpower | $349 | 100+ | $3.49 |
| $349 | 75+ | $4.65 | |
 WHOOP Advanced Labs | $349 | 65 | $5.37 |
 Function Health | $365 | 160+ | $2.28 |
| $365 | 100+ | $3.65 | |
| $495 | 80+ | $6.19 | |
| $499 | 100+ | $4.99 | |
| $700 | 138 | $5.07 | |
| $829 | 54 | $15.35 | |
| $895 | 100+ | $8.95 | |
| $996 | 59 | $16.88 | |
| $1188 | 70+ | $16.97 | |
| $1198 | 40+ | $29.95 | |
| $1950 | 130+ | $15.00 |
$/Biomarker is annual cost divided by the panel's advertised biomarker count, not the price of this one test. We track 23 blood test providers (32 plans); 21 of those plans are itemized marker by marker. Compare all of them.
2 itemized panels do not include Apolipoprotein B (ApoB)
11 providers not itemized in our matrix
We have not itemized these marker by marker (some sell tests one at a time), so this page cannot say whether they offer Apolipoprotein B (ApoB). Check with them directly.
Life Extension Standard · Quest Health · Ultrahuman Blood Vision · Lifeforce · Hundred Health · Personalabs · Walk-In Lab · HealthLabs · WHOOP Specialized Panels · Marek Health Essential · Vitality Blueprint Upload
Experts discussing Apolipoprotein B (ApoB)
Podcast episodes where clinicians and researchers cover this marker in depth. Curated by hand; an episode is listed only when the marker is a substantial topic, not a passing mention.
- Sky High LDL on Keto/Carnivore: Should You Worry?
- Q&A #72: Fragmented sleep, lipid biomarkers including ApoB and Lp(a), statins and Repatha
- Aliquot #109: Reducing ApoB with diet, drugs, and supplements
- Don't Die Podcast #4: The Biomarker Strategy That Made Bryan Johnson the World's Healthiest HumanDisclosure: This is Bryan Johnson's podcast; Johnson owns Blueprint, which appears in our blood-test comparisons.
- Assessing cardiovascular risk (Lipid Series Part 2) | Tom Dayspring
- Essential Cardiovascular Risk Laboratory Analysis | Tom Dayspring
Frequently Asked Questions
What is the optimal range for Apolipoprotein B (ApoB)?
Published positions differ: <100 mg/dL moderate risk; <80 high risk; <65 very high risk (2019 ESC/EAS dyslipidaemia guidelines); ≥130 mg/dL is a risk-enhancing factor (2018 AHA/ACC cholesterol guideline). Named practitioners target: <90 mg/dL (<60 for those with high risk of arterial occlusion) (Life Extension); <70 mg/dL (Tracey O'Shea (Kresser Institute)). Lab reference interval: About 50-150 mg/dL (MedlinePlus); labs vary. That is what a lab report flags against, not an optimal target.
Which blood test providers include Apolipoprotein B (ApoB)?
19 of the 21 blood testing panels we itemize marker by marker include Apolipoprotein B (ApoB) in their panels. This biomarker is widely available across major providers.
Related: YouBoost rates lifestyle and supplement interventions by evidence; HRV Zone tracks recovery trends.
Medical Disclaimer
This information is for educational purposes only and is not medical advice. Always consult with a qualified healthcare provider about your specific health needs.
Last reviewed Sep 23, 2026 · First published Sep 30, 2025